Fujifilm Diosynth Biotechnologies North Carolina Inc., a contract development and manufacturing organization (CDMO), will invest $1.2 billion to expand its biopharmaceutical manufacturing facility in Holly Springs, North Carolina, creating 680 new jobs in Wake County. Initial investments of the Fujifilm’s Holly Springs operation included $2 billion in 2021, making it the largest end-to-end biopharmaceutical manufacturing facility in North America.
“North Carolina is known worldwide as a biotechnology hub thanks to the continued investment from companies like Fujifilm Diosynth,” said Christopher Chung, CEO of the Economic Development Partnership of North Carolina. “Our robust infrastructure, top-notch engineering talent in the state, and partnerships with entities like North Carolina State University and the North Carolina Biotechnology Center provide support for innovative companies like Fujifilm to continue to grow.”
In October 2023, North Carolina Governor Roy Cooper, North Carolina Department of Commerce Secretary Sanders and Christopher Chung met in Japan with leaders from Japanese businesses in North Carolina, including Fujifilm President and CEO Teiichi Goto, to discuss the continued partnership and the company’s facilities in the state. FujiFilm Diosynth Biotechnologies’ expansion includes an additional large-scale monoclonal antibody Drug Substance manufacturing capacity that will support the company’s growing biologics CDMO business. The project will also include two additional drug substance manufacturing buildings, a shared headblock building with administrative space, as well as expansions of utilities, lab, and warehouse buildings currently under construction. The average salary for new positions at Fujifilm Diosynth Biotechnologies will be $109,923, which is notably 46% higher than Wake County’s average wage of $74,866.
